Welcome to the Takeda Oncology Newsroom. This section is dedicated to providing the most up-to-date information about our company, our people and our science.
For other Takeda news releases, please visit the Takeda.com Newsroom.
Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial
Takeda Announces China NMPA Acceptance of New Drug Application for Mobocertinib (TAK-788) as a Treatment for Adult Patients with EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer